BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
Introduction I was surprised to read that no instrument exists to reliably assess the quality of the medication documentation. Is there a reference to support this or have others commented on the need for such a tool? Alternatively by including the word 'reliably', does that mean that there are some instruments but that they are not reliable? More detail here would be helpful background.
Methods
Study context. Mention is made of 'a sufficient sample of patient records' -was a sample size calculation employed? If not, why not?
Patient and public involvement. Please outline the patient consent process fully either here or in the section where the chart review method is described.
Development of MediDocQ.
More detail is required in the text about Figure 1 . Does Figure 1 document the local medication process? Do not assume that this process is the same in other international settings. For example, in many countries the hospital prescription sheet is the same as the medication sheet -i.e. the doctor writes the prescription on the medication chart and the nurse documents the administration all on the same page. It might be helpful to readers to provide an example of these sheets (blank) as an appendix.
Significantly more detail is required about the focused literature review and web-based search -i.e. search terms, inclusion/exclusion criteria, etc. Did the web search include international as we as local national guidelines? Outline fully how the results from these searches led to the formulation of the five core requirements. Were these five requirements solely obtained from the three articles referenced, how did the other search results contribute? The statements in Box 1 should be referenced individually.
More detail is required on the next stages in development of the tool. There should be sufficient information to enable the reader to understand the process. For example, does the paragraph on screening patient records in three different units correspond to the figure 2 box 'familiarisation' with patient records' (if yes then this should made clear in the text also), why were those three units chosen (and justify a general medical unit wasn't included), what is meant by the phrase 'specifics and variations'? Again more detail about the focus groups would be helpful -how were the participants chosen, were surgeons as well as physicians included, who facilitated the groups? Additional information regarding the focus group questions and the rating process of the instrument could be included in an appendix. Please also expand on the pre-test stage -e.g. were there significant changes required because of the pre-test?
Content of the MediDocQ instrument. How were the five core requirements translated into three key components? Was the structure of the instrument based on another validated instrument/tool? RCR procedure. Justify why the reviewers stopped the review at the second medication sheet.
Results
Provide the numbers for all stages of the record review (total number of records, number of records selected, number excluded for each reason -no consent, missing record, missing sheet etc). This detail could be given in a flowchart. Results of the 10% quality assurance should also be provided.
Discussion
This section needs to be tightened up. A few of the sentences are not entirely clear in their meaning -e.g. the sentences under Feasibility when using MediDocQ starting 'During RCR development and data gathering..' and 'In order to control for such unit and departmental level specifics,…'. Under Assessing the quality of documentation in medication process clarify what is meant by 'heterogeneous' -e.g. is this between departments or indices? The statements in the remainder of this paragraph need referencing. Under Strengths and limitations the statement that 'this study highlights the quality of medication documentation as an important proxy variable for patient safety' should be removed or qualified, as patient safety data was not collected. Under Implications for research and practice it is stated that the study has 'identified a need for efficient solutions to reduce the complexity of documentation process…' etc. I am not convinced that the results from this study have identified this. Either clarify this with specific reference to the supportive findings or remove the sentence.
Minor points -Introduction. Add references for the statement that 'it is a legal requirement to document all patient relevant information…'. Reference to international and local guidelines/legislation would be good here.
-Introduction, second paragraph: 'access' rather than 'excess' in sentence starting 'Prescriptions and orders,…'. -Methods, paragraph about focus groups: clarify what is meant by the terms 'unit-dose system or electronic documentation system'. Table 1 -indicate for each item whether they were rated on the Likert scale, yes/no or as counts. -Methods, RCR procedure, sentence starting 'All reviewers were instructed to focus…' -should it be 'prescription sheet' rather than 'medication sheet'? -Methods, RCR procedure, item 3) pro re nata (PRN) -clarify what is meant by 'different information'. -Methods, RCR procedure -what is meant by 'smooth information exchange'? -Results -the unabbreviated term should be used alongside the abbreviation QD when it is first used. -Results, sentence 'One possible reason for this was the sheet structure…' -this should be in the discussion.
-Results, completeness of information, bottom of page 11 -clarify in numerical or more specific descriptive terms what is meant by 'a huge number'. -Discussion -refers to a '79-item RCR instrument' whereas under content of the MediDocQ instrument the tool is described as having '54 items'. Please clarify.
-Discussion, last paragraph -references are required for many of the sentences in this paragraph.
-Has a STROBE checklist been completed?
GENERAL COMMENTS
Thank you for the opportunity to review this paper in which the authors describe the development and feasibility of an audit tool to assess medication documentation in hospitals.
Significance:
The authors describe a paper-based medication management process in a setting in which there is limited standardization in medication prescribing and administration documentation. This study will have limited generalizability in countries with nationally standardized medication charts and in settings in which medication prescribing and dose administration are documented on the same chart. In addition, the audit tool is of limited value in settings using electronic medication management systems (eMMS) where prescribing and administration details are also linked, avoiding the need for the transcribing of orders.
The medication use process described in this study is similar to that used in the USA prior to the majority of their hospitals transitioning to eMMS. The process involves medical staff prescribing on order sheets and nursing staff transcribing these orders on to an administration record -a process associated with a high risk of transcription errors. In contrast, in many countries, including Australia, the medications are prescribed by medical staff on a hospital medication chart and this same chart is used by nursing staff to document dose administration and by pharmacists to clarify aspects of the medication order (e.g. insert a generic medication name where a brand name is prescribed, or to clarify dose administration techniques such administering a dose via an enteral tube). In Australia, there has been a National Inpatient Medication Chart, with its own audit tool and annual audits for over a decade. These tools are gradually being modified as hospitals move to eMMS. Further details are available at:
https://www.safetyandquality.gov.au/our-work/medicationsafety/medication-charts/background-and-development-ofmedication-charts/national-inpatient-medication-chart-developmentand-background/ https://www.safetyandquality.gov.au/our-work/medicationsafety/nsmc-audit/ https://www.safetyandquality.gov.au/wpcontent/uploads/2018/09/National-Standard-Medication-Chartaudit-form-V1.0.pdf -Please make it clear in the Purpose that it is the quality of documentation of inpatient medication prescribing and administration that is being evaluated (not the documentation of the medication history as patients transition from the community into hospital -another source of medication error, but not the documentation specifically evaluated in this study).
-Please highlight in the Purpose that the study is evaluating 'paperbased non-standardized prescribing and medication administration charts'. This will provide the reader with some additional context for the study.
-Please clarify the number of items in the MediDocQ tool; the abstract and beginning of the Discussion state 79, but the Methods and Table 1 state 54 items.
-Please highlight whether patients were randomly selected or otherwise.
-The Results are very general and non-specific such that it is unclear how the results link to the conclusions drawn.
Introduction
-In the first paragraph where the authors describe several challenges in the medication use process, it would be valuable to highlight the impact that lack of standardization of documentation practices has on medication errors as well the difficulty of having staff move between units and hospitals when there is a lack of standardization in documentation processes and expectations. -Several important data elements appear to be missing from the audit tool that have been identified in the literature as contributors to medication errors. It would be valuable for the authors to note whether these elements were intentionally excluded or whether exclusion of such elements is a limitation of the tool. These include documentation of:
Methods a. Context
 at least 3 patient identifiers on each chart (to ensure the medications are being prescribed and administered to the correct patient),  documentation of allergy details (to ensure patients are not prescribed and administered specific medications to which they have had a previous allergic reaction to),  clarity as to the name (and contact details) of the prescriber (not only a signature, to ensure prescribers can be contacted for clarification),  documentation of body weight particularly for pediatric patients,  where there are multiple charts in use concurrently, clear marking of charts as 1 of x, 2 of x etc.  when medications were not administered, the reason for this non administration (e.g. nil by mouth, clinically inappropriate or an oversight).
d. Terminology
-To improve clarity for international readers, it would be worth changing 'medication sheet' to 'medication administration record (MAR)' as this is the term used in several countries.
-Also, rather than 'prescription with form of application', a more widely used term internationally for what appears to be intended here would be 'prescription with route of administration documented'.
e. Description of charts
-p7, line 30 -none of the units used unit dose systems or electronic documentation systems. It would be useful to note here whether the hospitals had standardized prescription and medication administration charts that were to be used by all units or did each unit have its own individual forms?
-How were medication orders ceased? Were prescription order forms a continuous form such that if a medication was to be ceased it would be recorded on the order form for the day or to cease a medication, did the prescriber need to go back to the original order and cease it against the original? If the later was the case, how is a nurse to know that a doctor has ceased an order?
-Whose responsibility was it to write up the second medication sheet? This can be a valuable time to review medications such as antibiotics to determine whether they need to continue, therefore it may be appropriate that not all medications on the first chart are transcribed to the subsequent chart. How was this situation handled?
e. RCR procedure -The years of practice experience of the chart assessors should be described. This is particularly relevant to the assessment of legibility. A new graduate with limited practice experience may not be able to accurately interpret a poorly written prescription, but a pharmacist with many years of clinical experience and experience deciphering doctor's prescriptions may have far fewer difficulties with legibility.
-In order for the tool to be useful to others who might want to use it for their practice and to assist the reader in understanding the data analysis, it would be worthwhile including a copy of the data collection tool as a supplementary document to the paper and include the how each element was scored.
f. Analysis
-It is unclear whether data was recorded and analysed by patient or by individual prescription. If each patient was scored once on each data element according to their entire regimen, how was a situation handled in which information was complete for some orders and incomplete for others? Was an overall 'impression' determined and a single score provided for each index? If a patient was prescribed two medications and one was deficient in its documentation how was this handled in contrast to a patient prescribed eight medications in which one was deficient in its documentation?
-Within table 1, it would be useful to include how each element was scored (e.g. binary or Likert scale). This is a well-written article on the development and use of a tool to assess medication ocumentation. However, significant additional information regarding the development of the tool is required for the reader to be able to assess the rigor of the approaches taken. In particular, more detail should be provided about the methods used in the literature review and development of the core requirements, the initial record screening, the focus groups, and the formulation of the key components of the tool. Were any of these stages based on validated tool development in other fields?
Results

-
Dear Reviewer 1, Thank you very much for your efforts and the valuable feedback given. Because MediDoCQ is such a complex instrument, we had some difficulties in writing this paper. However, thanks to your very clear and constructive suggestions, we made comprehensive changes in the text for improving the manuscript. We carefully considered comments and suggestions of both reviewer and revised several parts of the manuscript, but trying to keep word count in mind. Please find below a point-by-point response.
1. Abstract The abstract methods section should include the process used to develop the RCR instrument. Some sentences in the abstract seem to overreach the study's findings and should be clarified -e.g. the last sentence of the abstract purpose states that 'MediDocQ was critically appraised with regard to its contribution to patient safety improvement' and the last sentence of the conclusion states that 'the instrument can be used as an assessment for evaluating medication documentation as proxy for "patient safety"'. Please justify these statements. Answer: We added a summary of the process in the abstract and revised the statements.
2. Introduction I was surprised to read that no instrument exists to reliably assess the quality of the medication documentation. Is there a reference to support this or have others commented on the need for such a tool? Alternatively by including the word 'reliably', does that mean that there are some instruments but that they are not reliable? More detail here would be helpful background. Answer: We actually found a huge amount of studies concerning medication related adverse events (MRAE). However, these studies used different methodological approaches or focusses on specific MRAEs. We summarized these findings by adding more details and example studies in the introduction on p.7 3. Methods Study context. Mention is made of 'a sufficient sample of patient records' -was a sample size calculation employed? If not, why not? Answer: Yes, prior to the study we made a sample size calculation. 25 records were considered a sufficient sample. We added an information by the end of this paragraph on p.7. In preparation of the WorkSafeMed-study, a sample size calculation has been conducted. According to this we sought to review 25 patient records per unit, 4. Patient and public involvement. Please outline the patient consent process fully either here or in the section where the chart review method is described. Answer: In accordance with Editor's note we did not include the statement in the PPI statement, but reported in the statement on funding, ethics and consent to participate.
Development of MediDocQ.
More detail is required in the text about Figure 1 . Does Figure 1 document the local medication process? Do not assume that this process is the same in other international settings. For example, in many countries the hospital prescription sheet is the same as the medication sheet -i.e. the doctor writes the prescription on the medication chart and the nurse documents the administration all on the same page. It might be helpful to readers to provide an example of these sheets (blank) as an appendix. Answer: Figure 1 documents the general medication process commonly performed in Germany. We revised this paragraph and described the process of prescription and medication in more details. We refrained from attaching a blank example of the sheets in the appendix, mainly for copy right reasons.
6. Significantly more detail is required about the focused literature review and web-based search -i.e. search terms, inclusion/exclusion criteria, etc. Did the web search include international as we as local national guidelines? Outline fully how the results from these searches led to the formulation of the five core requirements. Were these five requirements solely obtained from the three articles referenced, how did the other search results contribute? The statements in Box 1 should be referenced individually. Answer: We did not perform an exhaustive systematic literature review but an unsystematic review focusing of certain search terms in order to find relevant paper supporting our assumptions on quality of documentation. We added the search terms to the literature review. Moreover, in the web bases search we focused on national guidelines for the documentation in German hospitals. However, international guidelines were noted as well. We found a few paper, and several interesting websites and reports. However the latter were note appropriate for scientific quotations, therefore we focused on these paper and documents confirming our argumentation. We revised the descriptions and added individual references for the statements in box 1.
7. More detail is required on the next stages in development of the tool. There should be sufficient information to enable the reader to understand the process. For example, does the paragraph on screening patient records in three different units correspond to the figure 2 box 'familiarisation' with patient records' (if yes then this should made clear in the text also), why were those three units chosen (and justify a general medical unit wasn't included), what is meant by the phrase 'specifics and variations'? Again more detail about the focus groups would be helpful -how were the participants chosen, were surgeons as well as physicians included, who facilitated the groups? Additional information regarding the focus group questions and the rating process of the instrument could be included in an appendix. Please also expand on the pre-test stage -e.g. were there significant changes required because of the pre-test? Answer: Along with feedback from reviewer 2 we revised the section on the MediDocQ development. We rephrased some terms and provided more details, even trying to limit the amount of information in the manuscript. Regarding the three units, we added more details to justify our selection on The documentation of the focus groups is quite compressive. We used photo documentation in case of the first two question (which is German) and wrote an extensive protocol on general results. For transparency in the process, it might be possible to attach additional files. However, we summarized important results on p.11, but believe any further information extends the scope and will not contribute to further understanding of the RCR. We also added a brief information on the sampling on p.11.
8.Content of the MediDocQ instrument.
How were the five core requirements translated into three key components? Was the structure of the instrument based on another validated instrument/tool? Answer: We added an example on how we translated the requirements on p.10. The structure came up in the process of development.
9. RCR procedure. Justify why the reviewers stopped the review at the second medication sheet. Answer: We rephrased the descriptions and added an explanation on p.13
Results
Provide the numbers for all stages of the record review (total number of records, number of records selected, number excluded for each reason -no consent, missing record, missing sheet etc). This detail could be given in a flowchart. Results of the 10% quality assurance should also be provided. Answer: We revised the first paragraph in section Sample and feasibility giving more details on number of excluded records and results on 10% quality assurance. Because it has been already a very time consuming approach to gain patient consents, we did not document refusal, but agreements.
Discussion
This section needs to be tightened up. A few of the sentences are not entirely clear in their meaninge.g. the sentences under Feasibility when using MediDocQ starting 'During RCR development and data gathering..' and 'In order to control for such unit and departmental level specifics,…'. Under Assessing the quality of documentation in medication process clarify what is meant by 'heterogeneous' -e.g. is this between departments or indices? The statements in the remainder of this paragraph need referencing.
Answer: Arguments were rephrased these sentences and added an example for the heterogeneous picture on p.20. We also added some references.
12. Under Strengths and limitations the statement that 'this study highlights the quality of medication documentation as an important proxy variable for patient safety' should be removed or qualified, as patient safety data was not collected. Answer: we removed this sentence from this section and rephrases this statement in the abstract and conclusion 13. Under Implications for research and practice it is stated that the study has 'identified a need for efficient solutions to reduce the complexity of documentation process…' etc. I am not convinced that the results from this study have identified this. Either clarify this with specific reference to the supportive findings or remove the sentence. Answer: We added a more detailed description on our results ahead and rephrased this argument on p.20 14. Minor points -Introduction. Add references for the statement that 'it is a legal requirement to document all patient relevant information…'. Reference to international and local guidelines/legislation would be good here. -Introduction, second paragraph: 'access' rather than 'excess' in sentence starting 'Prescriptions and orders,…'. Answer: Changed as suggested -Methods, paragraph about focus groups: clarify what is meant by the terms 'unit-dose system or electronic documentation system'. Answer: We corrected the term into the common "unit-dose-drug-distribution system" and moved this information to study design. In such a system pharmacist prepare medication for each units, such a system is usually combined with electronical documentation of medication. ) and number of documents (which documents?). Answer: With "document" we meant the different types of charts such as prescription chart, medication administration chart, PRN medication chart etc. We changed "document" into "chart" -Methods, Table 1 -indicate for each item whether they were rated on the Likert scale, yes/no or as counts. Answer: In accordance with Reviewer 2 we added the original answer scale in the RCR instrument in table 1 -Methods, RCR procedure, sentence starting 'All reviewers were instructed to focus…' -should it be 'prescription sheet' rather than 'medication sheet'? Answer: Agree and changed -Methods, RCR procedure, item 3) pro re nata (PRN) -clarify what is meant by 'different information'. Answer: We added the following information in Brackets: "… information (such as specified symptoms or indications for use and maximum daily dose)." -Methods, RCR procedure -what is meant by 'smooth information exchange'? Answer: We changed smooth into "timely and direct" -Results -the unabbreviated term should be used alongside the abbreviation QD when it is first used. Answer: At some point in the writing process, we changed the labels of the sub-indices from Quality Documentation (QD) into the more clear distinction G(eneric) and A(dditional) aspects, however we missed doing this in the text as well. So thanks for pointing this out. We changed the labels in the text on p15ff in accordance with tables and figures and introduced them in the method section on p12.
-Results, sentence 'One possible reason for this was the sheet structure…' -this should be in the discussion. Answer: We did not move that one due to word count reason. We think this comment is relevant to this results but found it difficult to move to discussion without raising a completely new issue and adding even more text.
-Results, completeness of information, bottom of page 11 -clarify in numerical or more specific descriptive terms what is meant by 'a huge number'. Answer: We added means and SD for this item in brackets: "(item 16, item mean=.17, SD=.35)." -Discussion -refers to a '79-item RCR instrument' whereas under content of the MediDocQ instrument the tool is described as having '54 items'. Please clarify. Answer: For explanation, the entire instrument consist of 79 items, including the 54 items measuring the generic and additional aspects and additional open ended items for detailed explanations if required as well as initial items, for example to document the number of charts for prescriptions. We added more details on the remaining items in the section content of MediDocQ.
-Discussion, last paragraph -references are required for many of the sentences in this paragraph. Answer: We added a few references and examples from our findings underpinning our argumentation -Has a STROBE checklist been completed? Answer: Yes, now attached to the manuscript Reviewer: 2 Reviewer Name: Simone Taylor Institution and Country: Austin Health, Australia Please state any competing interests or state 'None declared': none declared Thank you for the opportunity to review this paper in which the authors describe the development and feasibility of an audit tool to assess medication documentation in hospitals. Significance: The authors describe a paper-based medication management process in a setting in which there is limited standardization in medication prescribing and administration documentation. This study will have limited generalizability in countries with nationally standardized medication charts and in settings in which medication prescribing and dose administration are documented on the same chart. In addition, the audit tool is of limited value in settings using electronic medication management systems (eMMS) where prescribing and administration details are also linked, avoiding the need for the transcribing of orders. The medication use process described in this study is similar to that used in the USA prior to the majority of their hospitals transitioning to eMMS. The process involves medical staff prescribing on order sheets and nursing staff transcribing these orders on to an administration record -a process associated with a high risk of transcription errors. In contrast, in many countries, including Australia, the medications are prescribed by medical staff on a hospital medication chart and this same chart is used by nursing staff to document dose administration and by pharmacists to clarify aspects of the medication order (e.g. insert a generic medication name where a brand name is prescribed, or to clarify dose administration techniques such administering a dose via an enteral tube). In Australia, there has been a National Inpatient Medication Chart, with its own audit tool and annual audits for over a decade. These tools are gradually being modified as hospitals move to eMMS. Further details are available at: https://www.safetyandquality.gov.au/our-work/medication-safety/medication-charts/background-anddevelopment-of-medication-charts/national-inpatient-medication-chart-development-and-background/ https://www.safetyandquality.gov.au/our-work/medication-safety/nsmc-audit/ https://www.safetyandquality.gov.au/wp-content/uploads/2018/09/National-Standard-MedicationChart-audit-form-V1.0.pdf Dear Reviewer, Thank you very much for your efforts and the valuable feedback given. Because it is such a complex instrument, we had some difficulties in writing this paper. Therefore, we very much acknowledge your obvious expertise in this research field and picked up lots of your issues raised and suggestions to provide examples in the manuscript and revise especially with regard to terminology and compressibility.
Concerning the international standardization, we are aware about developments in countries such as Australia that provide high standards for medications process and the documentation. However, there's still many countries, especially in Europe, with low standardization or which are currently in transition to including several highly vulnerable processes, were we believe this tool is of great value.
We carefully considered comments and suggestions of both reviewer and revised several parts of the manuscript, but trying to keep word count in mind. Please find below a point-by-point response.
Recommended revisions: This paper would benefit from major revision to improve its clarity and readability as outlined below: 1. Abstract -Please make it clear in the Purpose that it is the quality of documentation of inpatient medication prescribing and administration that is being evaluated (not the documentation of the medication history as patients transition from the community into hospital -another source of medication error, but not the documentation specifically evaluated in this study). Answer: changed as suggested -Please highlight in the Purpose that the study is evaluating 'paper-based non-standardized prescribing and medication administration charts'. This will provide the reader with some additional context for the study. Answer: revised a suggested -Please clarify the number of items in the MediDocQ tool; the abstract and beginning of the Discussion state 79, but the Methods and Table 1 state 54 items. Answer: For explanation, the entire instrument consist of 79 items, including the 54 items measuring the generic and additional aspects and additional open ended items for detailed explanations if required as well as initial items, for example to document the number of charts for prescriptions. We added more details on the remaining items in the section content of MediDocQ.
-Please highlight whether patients were randomly selected or otherwise. Answer: Please see response to point 3b -The Results are very general and non-specific such that it is unclear how the results link to the conclusions drawn. Answer: we revised our conclusion.
2. Introduction -In the first paragraph where the authors describe several challenges in the medication use process, it would be valuable to highlight the impact that lack of standardization of documentation practices has on medication errors as well the difficulty of having staff move between units and hospitals when there is a lack of standardization in documentation processes and expectations. Answer: we included some more details including your suggestions in the introduction on p.5 3. Methods a. Context -It would be valuable for the authors to describe the context of the study more fully, particularly for an international audience. For example, what is the role of pharmacists in the medication use process? Are they based on the units, reviewing charts and clarifying orders in order to optimize medication safety? Answer: We revised the first paragraph in the section on the Development of MediDocQ. Pharmacist are rarely directly involved in this process -It appears that there is a lack of standardization between units within each hospital, therefore it would be valuable to know whether the hospitals have Drug and Therapeutics Committees or Medication Safety Committees responsible for the development and implementation of safe medication use processes across their hospital (e.g. documentation policies, specific medications that can be nurse initiated)? Do the hospitals have policies regarding appropriate abbreviations and which abbreviations are considered error prone and should not to be used? Answer: To our knowledge, both hospitals had not at the time of our inquiry. However, point mentioned by you, were indeed results derived from the focus groups. Therefore, we added some more details on conclusion from focus groups on p.10. In relation to a different point of yours regarding item numbers, we used this as an example for one of the open-ended questions.
b. Patient/public involvement -The current statement could be moved to an acknowledgement section in the paper. Answer: statement is moved -It appears that patients needed to provide informed consent for their records to be included in the study. Does this mean that patients without the capacity to provide informed consent were excluded e.g. patients with confusion, delirium, dementia? What impact would this potential selection bias have on the results? Were patients randomly selected to be included in the study? How many patients were excluded because they were unable to or refused consent?
Answer: We added a more detailed description of inclusion and exclusion criteria and also added a limitation in the discussion section. Because it has been already a very time consuming approach we did not document refusal, but agreements.
c. Development of MediDocQ -The literature review appears to have been incomplete as there are several papers published that describe the audit tool used in Australia and I believe similar tools are available in other countries such as New Zealand and UK (e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477322/ ). Answer: The literature described in the manuscript solely refers to identify relevant appraisal criteria for evaluating the quality of medication documentation. However, we are aware, that a huge number of studies exist, to measure MRAE. But these studies These studies either use observational study designs (such as audits or surveys) -or they refer to medication processes at hospital admission and discharge or they focus on the prevalence of specific MRAE (such as overdose, contra indication. We updated the introduction with this information. Moreover, we also aware of tools like in-patient prescription chart (as you recommended) and choose to refer to such tool in the implication section of out manuscript.
-Several important data elements appear to be missing from the audit tool that have been identified in the literature as contributors to medication errors. It would be valuable for the authors to note whether these elements were intentionally excluded or whether exclusion of such elements is a limitation of the tool. These include documentation of: Answer: We are afraid, but these points might be a consequence of lacking standardization or this is due to "German"procedures:
• at least 3 patient identifiers on each chart (to ensure the medications are being prescribed and administered to the correct patient), Every chart usually contains the Name and birthdate of the patient, in some cases charts are labeled with tags (containing information on name, age, admission date and hospital case number). In our hospitals, all charts are provided in the same patient record. Reviewer were instructed to control for names (e.g. to at least compare with names from informed consents given), but we did not rate these information. Moreover, within the purpose of our study, we were not able to control the actual process of medication administration and ensure such identifier were used.
• clarity as to the name (and contact details) of the prescriber (not only a signature, to ensure prescribers can be contacted for clarification), The prescription and administration templates solely have enough space for either initials or signature., there exists no official standards on how to sign a prescription or medication administration. Physicians usually sign the prescription, while nurses initial administration or just tick them off. Moreover, usually nurses solely intial s.c. or i.v. drugs, but rarely oral medication. Some units provide a list containing initials / signature of all nurses and physicians working in this unit. Again, we did not find standards; neither knew the professions in the focus group about some within the hospitals. They rather reported different procedures, especially in case of nurses' documentation. We mentioned one example in the description of the focus groups.
• documentation of allergy details (to ensure patients are not prescribed and administered specific medications to which they have had a previous allergic reaction to), • documentation of body weight particularly for pediatric patients, Answer: We absolutely agree with the reviewer this being important information! This information is documented in the anamnesis and we did find hints on allergies (e.g. plaster or penciling) in the medication administration charts. However, we did not consider for MediDoc, because of feasibility reasons. MediDocQ is not intended to cover actual medication errors such overdose, drug interactions or allergic reactions, or specific medication such as cytotoxic therapy, were the weight is essential information.
• when medications were not administered, the reason for this non administration (e.g. nil by mouth, clinically inappropriate or an oversight).
Answer: Even we did not report in detail, such information is covered with the open ended questions. In this specific case reviewer were instructed to review additional charts such as daily shift notes from nurses or physician and provide more information in open-ended questions. We added this example on p.12.
d. Terminology -To improve clarity for international readers, it would be worth changing 'medication sheet' to 'medication administration record (MAR)' as this is the term used in several countries. -Also, rather than 'prescription with form of application', a more widely used term internationally for what appears to be intended here would be 'prescription with route of administration documented'. Answer: Thank you very much for these valuable information regarding terminology. We changed several terms as follows: We generally exchanged the term "sheet" with "chart", since this appears to be a common term. "medication sheet" is changed into "medication administration chart", because this is a single chart in the patient record. "form of application" is changed into "'route of administration" We additionally changed "medication stopped" into "medication ceased" e. Description of charts -p7, line 30 -none of the units used unit dose systems or electronic documentation systems. It would be useful to note here whether the hospitals had standardized prescription and medication administration charts that were to be used by all units or did each unit have its own individual forms? Answer: We corrected the term to "unit dose drug distribution system" and moved this information to study design. We also agree about the necessity to note the lack of standardization, however with this revision we pointed this out earlier in in the beginning of the section Development of MediDocQ.
-How were medication orders ceased? Were prescription order forms a continuous form such that if a medication was to be ceased it would be recorded on the order form for the day or to cease a medication, did the prescriber need to go back to the original order and cease it against the original? If the later was the case, how is a nurse to know that a doctor has ceased an order? Answer: This indeed is an important point. Generally, the medication is ceased by order of the treating physician in the prescription sheet. We found both options in the records, daily orders and continuing orders -even within units. Considering the information of nurses, we knew from focus groups and previous experience, some patient record systems (e.g. provided by OPTIPLAN https://www.optiplan.org/) allow pulling colored marker. In other cases, nurses join the ward rounds or nurses are informed directly by physicians. To our knowledge, there exist no standardized process for informing nurses about changes in the prescription. Using MediDocQ, we were able to review inappropriate ceasing medication in charts, when e.g. medication was documented to be administered (G09: Timely adjustment in medication). For this manuscript, we solely added a brief information on the handling of medication adjustment (inclusive ceased medication) in the Beginning of the section development of MediDocQ. However, since the issue raised by you can only be measured using observational study design, we refrained to discuss in detail.
-Whose responsibility was it to write up the second medication sheet? This can be a valuable time to review medications such as antibiotics to determine whether they need to continue, therefore it may be appropriate that not all medications on the first chart are transcribed to the subsequent chart. How was this situation handled? Answer: This actually is nurses responsibility. Again, there is no standardized process, but usually nurses copy the list of medication from the first medication administration chart to the other, by crosschecking up to date medical orders on prescription sheet. This is a highly error-prone process, which is why we chose to include this transcription in the review process. Reviewer were instructed to first check the transcription from first to second chart and carefully compare the transcription in the second chart with the latest medical prescriptions and adjustments.
Answer: We agree that new graduates with limited practical experience may not be able to accurately interpret a poorly written prescription. However, in reality even young professionals such as residents and nurses in training are expected to deal with poorly written prescriptions. Therefore and as one of the reason, each reviewer rated all charts within one unit. In case of unreadable information in the charts, reviewer were instructed to stop the review and consult the supervisor for help before continuing the review.
-In order for the tool to be useful to others who might want to use it for their practice and to assist the reader in understanding the data analysis, it would be worthwhile including a copy of the data collection tool as a supplementary document to the paper and include the how each element was scored. Answer: we added the information, that the tool is available on request f. Analysis -It is unclear whether data was recorded and analysed by patient or by individual prescription. If each patient was scored once on each data element according to their entire regimen, how was a situation handled in which information was complete for some orders and incomplete for others? Was an overall 'impression' determined and a single score provided for each index? If a patient was prescribed two medications and one was deficient in its documentation how was this handled in contrast to a patient prescribed eight medications in which one was deficient in its documentation? Answer: Data were analyzed on patient level. This information was added in the statistical analyses. Concerning the amount of medication or prescriptions we used counts and the proportion of two variables to control for. E.g. proportion of medications prescribed, but not transcribed into medication administration chart (r*) = proportion of 2 variables counting (1) newly prescribed medication in prescription chart and (2) and not transcribed orders in medications administration chart. However most items use the 4-point Likert scale (no, somewhat no, somewhat yes, yes) and reviewer were instructed to rate upon a "50/50" rule. E.g. With item 10 (Medications such as tablets, drops, ointments, eye drops, inhalants or enemas (p.o. rectal, cutaneous etc.) generally initialled by physician/nurse when administered)), reviewer rated somewhat no, when more than half of the medication was not initialed and no, when (almost) none of the medication was initialled.
-Within table 1, it would be useful to include how each element was scored (e.g. binary or Likert scale). Answer: In accordance with Reviewer 1 we added the original answer scale in the RCR instrument in table 1 4. Results -It appears that there could be several documents where doctors could document prescriptions. In those 217 patients in which prescriptions were documented in more than one document, was there a higher number of orders missed by the nurses when transcribing onto the medication chart?
Answer: This indeed is an interesting question. Computing a simple T-Test with item 34 "Proportion of medications prescribed, but not transcribed into medication administration chart (r)" we found significant better values in case of just one chart, compared to cases with prescription in 2 or more charts. Even these results are interesting we refrained from mentioning in the manuscript, since this would raise only more interesting additional questions to be analyses and overload the paper with information.
5. Discussion -What is meant by p13, line 43, '….for such unit and departmental level specifics, reviewers were instructed to report all specifics in one open ended question'? Answer: We added an example -What is meant by p14, line 13, '…delays in documentation play a role or where additional effort must be taken to ensure documentation…' Answer: we changed the examples to make it clearer -Implications for the future -it would be valuable to highlight the importance of standardization of documentation across units and hospitals as a mechanism to improve medication safety and minimize errors, particularly as staff move between units and hospitals. Answer: This actually is one of our main points. We rephrased a couple statements to make that more clear.
6. Box 1 -The meaning of the second sentence explaining 'Transparency' should be worded more clearly. 'Uniqueness' does not appear to be the correct term; would 'Clarity of intent' be closer to what is intended? 'Timeously' in the explanation of Timeliness; would ' in a timely manner' more clearly express what is intended? Answer: We rephrased the explanations in box 1 7. Figures -The title and 3 columns need to be more clearly labelled. I assume the first column of plots are for the single items, the second for the sub-indices and the third for the main indices. I assume the numbers are the mean scores and the lines are the standard deviations. It is unclear what the shaded areas pertain to -are these bar graphs of the means? If this is the case a simple dot point within the s.d. would be clearer than a bar graph of the mean. Answer: In case of figure 3 we added headlines and additional notes and restructured the 8 graphs in accordance to the three key components ((1) Completeness of information, (2) Quality of, and (3) Compliance with chart structure, legibility and handling of deletions and corrections in charts. We also conserved the option using dot points, but sticked to the bar graphs.
8. Some copy editing and clarification of wording would be valuable: -p4, line 45 "…not only high concentration, for example in preparing medications, but also fully informed staff…" Answer: we rephrased the sentences -p8, line 1 "…for administering it to the patient with pencil in the medication sheet…". This sentence is clumsy and could be more clearly expressed. Answer: we rephrased the sentences -p13, line 41 -what is meant by domestic specific regulations? Answer: we changed into "local" -p19, line 37 "Single prescription with multiple entries". It is unclear what this is assessing?
Answer: example added in table 1, as we did for other items which required more detailed explanations -p21, line 46 "..proportion of not enough or too much changed medication". Is this meaning that the dose documented did not match the dose prescribed? Answer: example added - 
GENERAL COMMENTS
The authors have addressed my comments satisfactorily.
REVIEWER
Simone Taylor
Austin Health, Australia REVIEW RETURNED 13-Jan-2019
GENERAL COMMENTS
Overall, the authors have greatly improved the manuscript in terms of highlighting its significance and applicability to several countries, particularly in Europe. The context of the study and methodology are more clearly described. The manuscript would benefit from a further major revision, particularly to assist readers wanting to replicate the authors' study in their setting.
Now that the rating scales used to report each of the items have been clarified (particularly in table 1), major concerns regarding the appropriateness of the analysis are highlighted. Morphing binary, ordinal and proportional data into continuous variables so that means and standard deviations can be calculated for mainindices, sub-indices and individual items is not appropriate; the scoring system appears very arbitrary. It would seem more appropriate to report the proportion of patients whose record was rated as 'all yes or mostly yes' for each item. Given that items were rated once per patient, most of whom were taking several medications, it is unclear how many of the yes/no rated items can be answered with a simple binary response. I would highly recommend either the journal or the authors source the input of a biostatistician.
Throughout the attached tracked document, I have added several additional comments. I have edited some passages to improve clarity or express information more succinctly. There remain several sections where information could be expressed more efficiently in order to not exceed the recommended word count.
-The reviewer provided a marked copy with additional comments. Please contact the publisher for full details. Overall, the authors have greatly improved the manuscript in terms of highlighting its significance and applicability to several countries, particularly in Europe. The context of the study and methodology are more clearly described. The manuscript would benefit from a further major revision, particularly to assist readers wanting to replicate the authors' study in their setting.
REVIEWER
Dear Reviewer 2, Thank you very much once again for your efforts in reviewing our manuscripts and your general feedback on our revision. Please find a point by point answer regarding your suggestions for further revisions. Moreover, please find additional comments to yours in the paper in the attached file: Hammer_2018_Chart Review Development _190503 _tracked with reviewer comments and answers. Now that the rating scales used to report each of the items have been clarified (particularly in table 1), major concerns regarding the appropriateness of the analysis are highlighted. Morphing binary, ordinal and proportional data into continuous variables so that means and standard deviations can be calculated for main-indices, sub-indices and individual items is not appropriate; the scoring system appears very arbitrary. It would seem more appropriate to report the proportion of patients whose record was rated as 'all yes or mostly yes' for each item. Given that items were rated once per patient, most of whom were taking several medications, it is unclear how many of the yes/no rated items can be answered with a simple binary response. I would highly recommend either the journal or the authors source the input of a biostatistician.
Answer: We are aware, that from a statistical point of view, this scale is not a continuous scale and further investigations may require different statistical approaches. However, in developing the instrument we have been challenged by, on the one hand, ensuring an easy rating which is easily interpretable and judgeable by all reviewers and, on the other hand, still being able to use the variables in further analyses with the survey data. With both, the developmental process of MediDocQ as well as the calculations of the items and indices were advised by Peter Martus (a bio-statistician and member of the research consortium) who approved the final statistical analysis. Moreover, and with regard to the latter point, we provided a more detailed description on the rating scales and how the reviewer were instructed to rate on the Likert and yes/no scales in the section "Content of the MediDocQ instrument".
In general, we thought to summarize items into sub-indices and main-indices for being able to present the data on uniform scales. Thus we, transformed the Likert scale into a 100% scale, which is quite common in health services research. The binary items were rated with either 0 or 1 (the item e.g. pencil documentation was either true or not, independent from the number of medication), thus we calculated means of single items across the sample. A value of .65 would inform us that 65% of the records fulfilled this criterion. With regard to the counts we calculated proportions (as stated in the overview in table 1). E.g. item 5: Prescription with dose, we calculated the proportion of prescriptions ordered with doses and all prescriptions and received values between 0 and 1). We finally combined these information by calculation sub-and main indices. We carefully considered other approaches, as the one you suggested, (proportion of patients who had each item rated as 'yes' or even 'yes') in previous stages of this project. However, by dichotomizing the Likert scales, we would lose too much "information" from the items due to aggregation. Moreover, this solution again would not really fit to the dichotomous answers and counts.
Nevertheless, we agree, this is a sensitive issue and thus we made it a point in the limitation section of this study.
Answer: We copy pasted your comments and suggestions into the document for this revision and attached an additional file with a detailed feedback on your suggestions and revisions (file name = Hammer_2018_Chart Review Development _190503 _tracked with reviewer comments and answers). Please leave your comments for the authors below I think the research study clearly described in this manuscript has been well conducted. I have only two questions:
1. It is mentioned that this study involves two hospitals. Were the results in the two locations sufficiently similar, such that separate analyses are not necessary?
Answer: We found some statistically significant differences between the two hospitals. However, interpretation would be difficult without additional data sources and presenting these results would go beyond the purpose of this paper. Therefore, we carefully considered but decided to present descriptive results together for both hospitals.
2. One of the conclusions is that there seems to be an association between documentation delay and documentation quality. Why not conduct a formal statistical test of significance to confirm this conclusion? Perhaps simply a two-sample t-test, comparing the mean quality in two groups (instances without delay vs. instances with delay). I believe the necessary data for such a test would be available in your records.
Answer: Thank you very much for this comment. We totally agree and it would have been nice to test for our assumption, which was a result from discussions with professionals. However, we do not have data on documentation delay. Nonetheless, we will consider this point with further analyses with the survey data from this project.
VERSION 3 -REVIEW
REVIEWER
Simone Taylor Austin Health, Australia REVIEW RETURNED 24-May-2019
GENERAL COMMENTS
Thank you for submitting your second revision of this paper and for addressing each of my comments in the tracked copy. Whilst the study is more clearly described than originally, several issues previously raised remain outstanding and need to be addressed prior to publication. 1. I understand the author's desire to develop a pragmatic RCR tool that can be readily used by hospital staff as part of a quality improvement program. I also understand that one of the consortium members is a bio-statistician and that on occasions ordinal variables (such as 0-10 visual analogue pain scores) are approximated to continuous variables. Several of my concerns regarding the statistical analysis remain and I feel it is incumbent upon the Journal to seek an independent statistical review. Key issues to address are: -Approximating dichotomous variables with yes/no answers to continuous variables and reporting these as means and standard deviations is very problematic. To report 4-point 'Likert' scales (no, somewhat no, somewhat yes, yes) as means and standard deviations is also problematic as this assumes a normal distribution such that the difference between scores of 0-1, 1-2, 2-3, and 3-4 are equivalent. Combining scores from different types of data (counts/proportions, binary and ordinal data) into single scores also requires input from an independent statistician. -As outlined in detail on my tracked changes version of the second revision, the several rating scales reported in table 1 are ambiguous such that it would be difficult for a reader to use the RCR tool in their setting and compare their results to those from this study. >For example, for sub-index G02, it remains unclear to me why prescription name legibility, dose, dose unit and interval are reported as counts, whilst route of administration is reported differently as a 4-point 'Likert' scale. The authors explain that route is handled differently because oral administration is often not specified. This would not be an acceptable prescription in many hospitals around the world. It does not provide clarity regarding when a medication should truly be given orally versus via an enteral tube as is commonly required in hospitalized patients. Even if oral route is often not specified in the study hospitals, this should be reported in the same way as the dose, dose unit etc to highlight that route of administration is poorly documented. > Regarding reporting of 'counts' in table 1, in the author's reply they state these counts were converted to proportions. If this was the case, then the counts need to be changed to proportions in the -The description of the sample size calculation remains inadequate. The research question upon which this was based is unclear, the assumptions fed into the calculation are not reported and the level of significance/precision aimed for are not specified. How was the number of 25 records per unit arrived at? -The number of significant figures/decimal places is inconsistent throughout the manuscript. For example in the text, the median number of medications has no decimal places, whilst in table 2 it is reported to 2 decimal places and the mean is reported to 3 decimal places. 2. Overall, the entire manuscript could be expressed far more succinctly. Examples that I have provided in previous reviews have been incorporated, but I only gave some suggestions, without thoroughly revising the entire manuscript. Whilst the English expression in the paper is generally understandable, the manuscript still requires meticulous copy editing with particular focus on grammar, (including tenses and plural versus singular words), as well as punctuation (including commas).
VERSION 3 -AUTHOR RESPONSE
Comments from the Statistical Advisory Board (09-Jul-2019):
I have read the manuscript and the peer-review and have to agree with the reviewer's assessment of the study. I do not think the manuscript is publishable in its current state. Please see my comments below. Answer: Thank you very much for your review. As agreed with Edward Sucksmith, we made substantial changes to the statistics. Please find below a point by point feedback to your comments.
The paper is excessively long and lacks structure. Some statements are duplicated in different subsections leaving a reader confused about whether they belong to methods, results or discussion. Answer: The current length of the text is a result from our revisions on previous reviewer feedbacks, with most of them already accepted by the reviewer or made by the reviewer themselves. However, we agree and re-structured the argumentation and were able to shortened the main text by about 500 words.
The object of the study was to assess the quality of medication documentation using a developed instrument. No hypothesis was tested so conducting sample size calculations was irrelevant. It is unclear where the number of observations (the number of patient records per unit, 25) comes from and what it is supposed to facilitate. Answer: The introduction of the power calculation in the method has been a result of previous reviewer feedbacks. With regard to the main-question of the WorkSafeMed-study, our bio-statistician conducted a power calculation resulting in 25 records per unit. However, we agree with your argumentation and changed this information. As no hypothesis is tested, the sample size can be considered as a purposeful sampling.
The description of the instrument is confusing (page 11 paragraph 3) -"79 items structured into 8 themes measuring 16 components with a total of 54 items" -a proper explanation should be given to demonstrate the calculation and the terminology should be clarified (items vs items). Answer: With regard to the upper point, we focused on 54 items presented in table 1 and deleted the calculation of sub-and main-indices.
It is unclear why or which items are "not applicable" -this should be explained. The effect of missing values should be discussed and if applicable a sensitivity analysis should be designed. Answer: Along with your other comments on the calculation of sub-and main-indices we decided to skip the calculation of mean and sub-indices, but stick to the reporting of individual item results. As we now solely present descriptives of individual items, there is no effect of missing values. An example of items "not applicable" is given in the method section (Page 12).
The term '75-percentile' is used incorrectly (pager 14, line 2). Answer: We deleted this information
Overall, the statistical analysis needs a major revision. Using mean and standard deviation for a notnormally distributed variable is misleading, median and interquartile range should be used instead. Answer: The use of ordinals (especially Likert) scales is a common practice in health services research, as subjective assessments and opinions can hardly be expressed by ratio-scales. Moreover, these results are commonly presented by means and SD, thus we prefer the description with mean and SD. However, we also decided to present the median and interquartile range on originals answer scales of items in the tables as well. Moreover, and in order to avoid further violation of statistical requirements, we refrained from calculation indices, as the presentation of single items descriptives allow the same conclusions to our findings. We very much hope this is an acceptable compromise. (See also comments above, after discussion with editorial board)
Recoding the responses of the reviewers into a 0-1 scale and calculating means is not appropriate.
The graphs in their current state are not acceptable. I would suggest the authors use horizontal bar charts with proportion of different values per item to describe the results. Pooling the results from different items into sub-indices using means is not appropriate. Answer: With regard to your previous point, there is no pooling of results, as sub-and main indices are not calculated any more. However, ordinal Likert scales, are still recoded from values between 1-4 into values 0-1 with the purpose of reporting all items on the same range of values from poor=0 to high=1. Dichotom answer scales were reported original by the values 0 and 1. Values on continuous variables represent proportions between 0 and 1 (0-100%). We understood from editorial feedback, the calculation of mean values and SD was already agreed and exchanged the graphs with tables, which now solely contain results of single items.
I can see a way forward by attaching some scores to different items and calculating overall score. Depending on the distribution a relevant statistical method could then be applied to describe quality in a quantitative way Answer: Thank you very much for the advice. We very much hope the changes in the calculations are an acceptable compromise.
